The Technical Analyst
Revance Therapeutics Inc [RVNC]
- Stock Price, Forecast, Insider, Ratings, Fundamentals & Signals
Exchange: NASDAQ Global Market ->Biotechnology
Last updated: 27 Oct 2021 @ 03:34 am
-1.16% $14.01
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 096.14 mill |
| EPS: | -4.70 |
| P/E: | 0.000 |
| Earnings Date: | Aug 05, 2021 |
| SharesOutstanding: | 78.24 mill |
| Avg Daily Volume: | 0.990 mill |
| RATING 2021-10-25 |
|---|
| B+ |
| Neutral |
| RATING DETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/20 | 2/20 | 3/20 | 4/20 | 1/21 | 2/21 | |
| Revenue | ||||||
| Gr.Profit | n/a | n/a | ||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2021-10-13 | Foley Mark J | Sell | 42 096 | Common Stock |
| 2021-09-27 | Moxie Dwight | Sell | 1 675 | Common Stock |
| 2021-08-16 | Rankin Aubrey | Sell | 9 364 | Common Stock |
| 2021-08-15 | Rankin Aubrey | Sell | 4 949 | Common Stock |
| 2021-07-28 | Rankin Aubrey | Sell | 34 332 | Common Stock |
| INSIDER POWER |
|---|
| 3.66 |
| Last 100 transactions |
| Buy: 2 273 196 | Sell: 621 082 |
Forecast:
16:00 - $14.01
Live Trading Signals (every 1 min)
Forecast 1: 16:00 - $14.01
Forecast 2: 16:00 - $14.01
Forecast 3: 16:00 - $14.01
SCORE
-1.73
Sell
-1.73
Sell
Score Algorithm Version: 0.9L
Last version updated: Wed 21th July 2021
Last version updated: Wed 21th July 2021
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $14.01 (-1.16% ) |
| Volume | 1.156 mill |
| Avg. Vol. | 0.990 mill |
| % of Avg. Vol | 116.76 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
RVNC
Latest Press Releases
2021-10-26 18:45:00 - Press Release
Revance Therapeutics Shareholder Alert
Securities litigation partner james (josh) wilson encourages investors who suffered losses exceeding $50,000 in revance therapeutics to contact him directly to discuss their optionsnew york, new york--(newsfile corp. - october 26, 2021) - faruqi & faruqi, llp, a leading national securities law firm, is investigating potential claims against revance therapeutics, inc. ("revance therapeutics" or the "company") (nasdaq: rvnc).if you suffered losses exceeding $50,000 investing in revance therapeutics stock or options and would like to discuss your legal rights, call faruqi & faruqi partner josh wilson directly at 877-247-4292 or 212-983-9330 (ext. 1310). you may also click here...
2021-10-26 13:37:00 - Press Release
Investigation Alert: The Schall Law Firm Announces It Is Investigating Claims Against Revance Therapeutics, Inc. And Encourages Investors With Losses To Contact The Firm
Los angeles, california--(newsfile corp. - october 26, 2021) - the schall law firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of revance therapeutics, inc. ("revance" or "the company") (nasdaq: rvnc) for violations of the securities laws.the investigation focuses on whether the company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. revance is the subject of an fda form 483 posted on...
2021-10-26 10:49:00 - Press Release
Revance Therapeutics Investigation: Block & Leviton Is Investigating Revance Therapeutics, Inc. For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged To Contact The Firm
Boston, massachusetts--(newsfile corp. - october 26, 2021) - block & leviton is investigating revance therapeutics, inc. (nasdaq: rvnc) for potential securities law violations. investors who have lost money in their revance therapeutics, inc. investment should contact the firm to learn more about how they might recover those losses. for more details, visit https://www.blockleviton.com/cases/rvnc.what is this all about?on october 15, 2021, the u.s. food and drug administration (fda) issued a complete response letter (crl) to revance...
2021-10-26 01:37:00 - Press Release
Shareholder Alert: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Revance Therapeutics, Inc. - Rvnc
New york, oct. 26, 2021 /prnewswire/ -- pomerantz llp is investigating claims on behalf of investors of revance therapeutics, inc. ("revance" or the "company") (nasdaq: rvnc). such investors are advised to contact robert s.
2021-10-25 17:56:00 - Press Release
Revance Therapeutics Investor Alert
Securities litigation partner james (josh) wilson encourages investors who suffered losses exceeding $50,000 in revance therapeutics to contact him directly to discuss their optionsnew york, new york--(newsfile corp. - october 25, 2021) - faruqi & faruqi, llp, a leading national securities law firm, is investigating potential claims against revance therapeutics, inc. ("revance therapeutics" or the "company") (nasdaq: rvnc).if you suffered losses exceeding $50,000 investing in revance therapeutics stock or options and would like to discuss your legal rights, call faruqi & faruqi partner josh wilson directly at 877-247-4292 or 212-983-9330 (ext. 1310). you may also click here for...
Latest News
2021-10-18 20:29:00 - Business Wire
Lost Money in Revance Therapeutics, Inc.?
OAKLAND, Calif.--(BUSINESS WIRE)---- $RVNC--Gibbs Law Group is investigating potential claims on behalf of Revance investors.
2021-10-18 20:23:00 - PRNewsWire
RVNC EQUITY ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Revance Therapeutics, Inc. Investors with Losses to Inquire About Class Action Investigation - RVNC
NEW YORK, Oct. 18, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC) resulting from allegations that Revance may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Revance securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
2021-10-18 16:28:00 - Newsfile Corp
Revance Therapeutics Investor Alert
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Revance Therapeutics To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - October 18, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Revance Therapeutics, Inc. ("Revance Therapeutics" or the "Company") (NASDAQ: RVNC).If you suffered losses exceeding $50,000 investing in Revance Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for...
2021-10-18 15:29:00 - PRNewsWire
Ademi LLP Investigates Claims of Securities Fraud against Revance Therapeutics, Inc.
MILWAUKEE, Oct. 18, 2021 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Revance (NASDAQ: RVNC). The investigation results from inaccurate statements Revance may have made regarding its business operations and prospects.
2021-10-18 11:19:08 - Schaeffers Research
Revance Therapeutics Stock Nosedives on FDA News
Revance Therapeutics Inc (NASDAQ:RVNC) is plummeting today, last seen down 41.9% to trade at $13.21.
2021-10-18 09:39:00 - PRNewsWire
INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Revance Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES , Oct. 18, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ: RVNC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
2021-10-18 09:07:00 - Newsfile Corp
REVANCE THERAPEUTICS INVESTIGATION: Block & Leviton Is Investigating Revance Therapeutics, Inc. for Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
Boston, Massachusetts--(Newsfile Corp. - October 18, 2021) - Block & Leviton is investigating Revance Therapeutics, Inc. (NASDAQ: RVNC) for potential securities law violations. Investors who have lost money in their Revance Therapeutics, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/rvnc.What is this all about?On October 15, 2021, the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) to Revance...
2021-10-18 08:44:00 - The Motley Fool
These 2 Nasdaq Biotechs Are Making Huge Premarket Moves Monday
2021-10-18 08:31:33 - Market Watch
Revance Therapeutics plummets after FDA said it can't approve BLA of treatment for frown lines
Shares of Revance Therapeutics Inc. RVNC, +0.66% plummeted 34.7% toward an 18-month low in premarket Monday, which puts them on track for a record one-day selloff, after the company said the the Food and Drug Administration issued a Complete Response Letter (CRL) regarding the biotechnology company's treatment of glabellar, or frown, lines. The company said late Friday that FDA determined it could not approve the Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection in its present form, citing deficiencies related to an inspection of Revance's manufacturing facility.
2021-10-18 08:19:14 - The Motley Fool
Why Revance Therapeutics Stock Is Getting Crushed Today
